Abstract
Circulating tumor DNA (ctDNA) has been proven as a tool for detecting minimal residual diseases (MRD) in mid-to-late stage non-small cell lung cancers (NSCLCs) that received radio-, chemo-, immuno-, and/or targeted therapies. However, its usefulness in monitoring diseases in resectable stage I-III NSCLCs after curative surgeries has not been validated. It also remains not fully understood whether tracking evolutionary dynamics of tissues in ctDNA could improve the risk stratification.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
